TargetMol

Ureidopropionic acid

Product Code:
 
TAR-T4919
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4919-50mg50mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4919-100mg100mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4919-1mL1 mL * 10 mM (in DMSO)£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4919-200mg200mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ureidopropionic acid is an intermediate in the metabolism of uracil. More specifically it is a breakdown product of dihydrouracil and is produced by the enzyme dihydropyrimidase. It is further decomposed to beta-alanine via the enzyme beta-ureidopropionase. Ureidopropionic acid is essentially a urea derivative of beta-alanine. High levels of Ureidopropionic acid are found in individuals with beta-ureidopropionase (UP) deficiency. Enzyme deficiencies in pyrimidine metabolism are associated with a risk for severe toxicity against the antineoplastic agent 5-fluorouracil.
CAS:
462-88-4
Formula:
C4H8N2O3
Molecular Weight:
132.119
Pathway:
Metabolism
Purity:
0.98
SMILES:
NC(=O)NCCC(O)=O
Target:
Endogenous Metabolite

References

Suminobu I , Takeshi K , Makoto I , et al. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using 13C-uracil as an in vivo probe[J]. British Journal of Clinical Pharmacology, 2010, 60(6):584-593. Brown D G , Rao S , Weir T L , et al. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool[J]. Cancer & Metabolism, 2016, 4(1):11. Goedert J J , Sampson J N , Moore S C , et al. Fecal metabolomics: assay performance and association with colorectal cancer[J]. Carcinogenesis, 2014, 35(9):2089-2096. Sparidans R W , Bosch T M , J?rger M , et al. Liquid chromatography?tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and ?-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of Chromatography B, 2006, 839(1-2):45-53. Andr? B.P. van Kuilenburg, Meijer J , Dobritzsch D , et al. Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency[J]. Molecular Genetics & Metabolism, 2007, 91(2):0-164.